Literature DB >> 20102755

Iron chelator deferoxamine alters iron-regulatory genes and proteins and suppresses osteoblast phenotype in fetal rat calvaria cells.

Jonathan G Messer1, Paula T Cooney, Deborah E Kipp.   

Abstract

There are few studies describing the extent to which low iron status affects osteoblastogenesis, despite evidence that iron deficiency produces adverse effects on bone density. The purpose of this study was to evaluate alterations in intracellular iron status by measuring iron-regulated gene and protein expression and to describe development of osteoblast phenotype in primary cells treated with iron chelator deferoxamine (DFOM) during differentiation. Using the well-described fetal rat calvaria model, cells were incubated with 0-8 microM DFOM throughout differentiation (confluence to day (D) 21), or only during early differentiation (confluence to D13-15) or late differentiation (D13-15 to D21). Changes in intracellular iron status were determined by measuring alterations in gene and protein expression of transferrin receptor and ferritin light chain and heavy chain. Development of osteoblast phenotype was monitored by measuring expression of genes that are known to be up-regulated during differentiation, analyzing the percentage of mineralized surface area, and counting the number of multi-layered bone nodules at the end of culture. Results indicate that treatment throughout differentiation with 8 microM DFOM alters iron-regulated genes and proteins by mid-differentiation (D13-15) in a pattern consistent with iron deficiency with concomitant down-regulation of osteoblast phenotype genes, especially osteocalcin. Additionally, alkaline phosphatase staining was lower and there was about 70% less mineralized surface area (p<0.05) by D21 in wells treated throughout differentiation with 8 microM DFOM compared to control. Down-regulation of osteocalcin and alkaline phosphatase mRNA (p<0.05) and suppressed mineralization (p<0.05) was also evident at D21 in cells treated only during early differentiation. In contrast, treatment during late differentiation did not alter osteoblastic outcomes by D21. In conclusion, it appears that iron is required for normal osteoblast phenotype development, and that early rather than late differentiation events may be more sensitive to iron availability. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20102755     DOI: 10.1016/j.bone.2010.01.376

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  9 in total

1.  Bone Mineral Density in Population Long-Term Exposed to Rare Earth Elements from a Mining Area of China.

Authors:  Heming Liu; Haiyan Liu; Zenghua Yang; Kunzheng Wang
Journal:  Biol Trace Elem Res       Date:  2020-05-02       Impact factor: 3.738

Review 2.  Iron and 25-hydroxyvitamin D in postmenopausal women with osteoporosis.

Authors:  Nasser M Al-Daghri; Sobhy Yakout; Afnan Ghaleb; Syed Danish Hussain; Shaun Sabico
Journal:  Am J Transl Res       Date:  2022-03-15       Impact factor: 4.060

Review 3.  Copper, iron, and selenium dietary deficiencies negatively impact skeletal integrity: A review.

Authors:  Denis M Medeiros
Journal:  Exp Biol Med (Maywood)       Date:  2016-05-05

4.  Wnt5a is a key target for the pro-osteogenic effects of iron chelation on osteoblast progenitors.

Authors:  Ulrike Baschant; Martina Rauner; Ekaterina Balaian; Heike Weidner; Antonella Roetto; Uwe Platzbecker; Lorenz C Hofbauer
Journal:  Haematologica       Date:  2016-08-18       Impact factor: 9.941

5.  Neuroinflammation, oxidative stress, and blood-brain barrier (BBB) disruption in acute Utah electrode array implants and the effect of deferoxamine as an iron chelator on acute foreign body response.

Authors:  Cassie Bennett; Farrah Mohammed; Anabel Álvarez-Ciara; Michelle A Nguyen; W Dalton Dietrich; Suhrud M Rajguru; Wolfgang J Streit; Abhishek Prasad
Journal:  Biomaterials       Date:  2018-10-18       Impact factor: 12.479

6.  High dose deferoxamine in intracerebral hemorrhage (HI-DEF) trial: rationale, design, and methods.

Authors:  Sharon D Yeatts; Yuko Y Palesch; Claudia S Moy; Magdy Selim
Journal:  Neurocrit Care       Date:  2013-10       Impact factor: 3.210

7.  Iron regulates the expression of ferroportin 1 in the cultured hFOB 1.19 osteoblast cell line.

Authors:  Guo-Yang Zhao; Dong-Hua DI; Bo Wang; Peng Zhang; You-Jia Xu
Journal:  Exp Ther Med       Date:  2014-07-03       Impact factor: 2.447

Review 8.  Neuroprotective Therapies for Spontaneous Intracerebral Hemorrhage.

Authors:  Kathryn N Kearns; Natasha Ironside; Min S Park; Bradford B Worrall; Andrew M Southerland; Ching-Jen Chen; Dale Ding
Journal:  Neurocrit Care       Date:  2021-08-02       Impact factor: 3.210

Review 9.  Influence of Iron on Bone Homeostasis.

Authors:  Enikő Balogh; György Paragh; Viktória Jeney
Journal:  Pharmaceuticals (Basel)       Date:  2018-10-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.